Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide

Altimmune's pemvidutide met its primary endpoint of MASH resolution in the Phase 2b IMPACT trial, despite fibrosis results likely being limited by the trial's short 24-week duration. The drug's unique combination of MASH resolution and weight loss, coupled with low adverse event-related discontinuation rates, positions it competitively. This outcome, along with upcoming FDA meetings and new trials, supports its continued development path and an analyst's 'Strong Buy' rating for ALT stock, citing a large market opportunity.

Analysis

Altimmune, Inc. has achieved a critical development milestone with its GLP-1/glucagon receptor agonist, pemvidutide, meeting the primary endpoint of MASH resolution in its Phase 2b IMPACT trial. This success secures a continued development path and provides a basis for upcoming discussions with the FDA. While the trial did not achieve statistical significance on the secondary fibrosis endpoint, this is attributed to the study's short 24-week duration, suggesting longer-term trials could demonstrate this benefit. Pemvidutide exhibits a strong competitive profile by uniquely combining MASH resolution with weight loss and demonstrating the lowest rate of adverse event-related discontinuations. The forward outlook is supported by multiple catalysts, including a pivotal End-of-Phase-2 meeting with the FDA and the initiation of new trials for Alcohol Use Disorder and Alcohol-Associated Liver Disease, which could expand its market opportunity.

Key Decisions for Investors

• Investors should view the successful MASH resolution endpoint as a significant de-risking event for pemvidutide's development pathway, despite the inconclusive fibrosis data which may be resolved in longer-duration studies.
• Consider the drug's dual-benefit profile of MASH resolution and weight loss, coupled with a superior safety profile evidenced by low discontinuation rates, as a key competitive advantage in the metabolic disease market.
• Monitor the outcome of the upcoming End-of-Phase-2 meeting with the FDA, as this will be a critical near-term catalyst determining the path forward for a Phase 3 trial.
• Factor in the potential for market expansion beyond MASH, given the company's plans to initiate new trials for pemvidutide in alcohol-related liver and use disorders.